Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 2:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: BE-FAST Clear all
Completed Phase 3 Interventional Results available

Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes

NCT01336023
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide, insulin degludec, liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
146
States / cities
Birmingham, Alabama • Anaheim, California • Bermuda Dunes, California + 126 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2018 · Synced Sep 10, 2026, 2:29 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment

NCT04573582
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Enasidenib
Drug
Lead sponsor
Celgene
Industry
Eligibility
40 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 14, 2024 · Synced Sep 10, 2026, 2:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1617 in Healthy Adult Non-Asian and Japanese Subjects Including Assessment of a Food Effect

NCT04077879
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ASP1617, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Sep 10, 2026, 2:29 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Obstructive Sleep Apnea and Glucose Metabolism

NCT03408613
View directory record Official record
Conditions
Sleep Apnea, Glucose Metabolism Disorders
Interventions
Positive Airway Pressure, Supplemental Oxygen, Sham
Procedure
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
30 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 10, 2026, 2:29 PM EDT
Enrolling by invitation Not applicable Interventional

Increasing Uptake of EHR-enabled Population Health Outreach Strategies to Improve Diabetes Screening

NCT05730582
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Pre Diabetes
Interventions
Parkland Diabetes Detection Program (PDDP) Screening Invitation
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
500,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 10, 2026, 2:29 PM EDT
Recruiting Phase 2 Interventional

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Total-Body Irradiation, Venetoclax
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
336
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 259 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 10, 2026, 2:29 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Clinical Study on Rapid Antioxidant Protection and Immune Modulating Effects.

NCT05042674
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Placebo, Ergothioneine, 25 miligrams, Ergothioneine, 25 miligrams, daily for 1 week
Dietary Supplement
Lead sponsor
Natural Immune Systems Inc
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Klamath Falls, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Sep 10, 2026, 2:29 PM EDT
Recruiting Not applicable Interventional

Concentration of n-3 PUFA Monohydroxylated Derivatives in Adults With Obesity After n-3 PUFA Supplementation.

NCT06991296
View directory record Official record
Conditions
Obesity
Interventions
SPM Active®
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 10, 2026, 2:29 PM EDT
Completed Not applicable Interventional Results available

Feasibility of a Patient Directed Tool to Assess Heart Health Among Endometrial Cancer Survivors

NCT05796518
View directory record Official record
Conditions
Endometrial Cancer, Survivorship
Interventions
PREVENT Cardiovascular Health Assessment Tool, Survey, Interview Regarding Heart Health
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 10, 2026, 2:29 PM EDT
Completed Phase 1 Interventional

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

NCT02022982
View directory record Official record
Conditions
KRAS Mutant Non-Small Cell Lung Cancer, Solid Tumors
Interventions
Palbociclib, PD-0325901
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Sep 10, 2026, 2:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reactivating Specific Memories During Sleep in Conjunction with a Suppression Context

NCT04702750
View directory record Official record
Conditions
Sleep, Consolidation
Interventions
Targeted memory reactivation (odors), Targeted memory reactivation (sounds)
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 35 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Sep 10, 2026, 2:29 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

NCT02289482
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2838232 PIB (SDD), GSK2838232 PIB (API), Placebo, Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 10, 2026, 2:29 PM EDT
Completed No phase listed Observational

Gastric Ultrasound Assessment for Patients Taking GLP1 Agonists

NCT06003985
View directory record Official record
Conditions
Gastric Ultrasound, Glucagon-like Peptide 1, Point of Care Ultrasound
Interventions
Gastric Ultrasound Exam
Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 99 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Jacksonville, Florida • Albany, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 10, 2026, 2:29 PM EDT
Active, not recruiting Phase 4 Interventional

A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

NCT05203510
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Parenteral Treprostinil, Oral Treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
28
States / cities
Phoenix, Arizona • Fresno, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 10, 2026, 2:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Practicality of Intermittent Fasting and Its Effect on Markers of Aging and Oxidative Stress

NCT02132091
View directory record Official record
Conditions
Aging, Metabolism
Interventions
Intermittent Fasting, 400 IU Vitamin E, 1000 mg Vitamin C
Other · Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
19 Years to 30 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 10, 2026, 2:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Storytelling To Prevent Obesity and Encourage Responsive Feeding Practices in Young Children

NCT05994924
View directory record Official record
Conditions
Obesity, Childhood
Interventions
Educational Handout, Video Series, Group Discussion Sessions
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 10, 2026, 2:29 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Non-invasive Measurement of Cerebrovascular Reactivity After Traumatic Brain Injury

NCT02990078
View directory record Official record
Conditions
TBI
Interventions
Sildenafil citrate, Functional Near Infared Spectroscopy, Hypercapnia Challenge
Drug · Device · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Sep 10, 2026, 2:29 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma

NCT00784823
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib 1 mg/m2, Bortezomib 1.3 mg/m2, Bortezomib 1.6 mg/m2, Melphalan
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 76 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Sep 10, 2026, 2:29 PM EDT
Recruiting No phase listed Observational

WISE CVD - Continuation (WISE HFpEF)

NCT02582021
View directory record Official record
Conditions
Microvascular Coronary Dysfunction, Cardiovascular Disease
Interventions
Coronary Angiography, Coronary Reactivity Testing, Cardiac Magnetic Resonance Imaging, Cardiac Magnetic Resonance Angiography, Computed Coronary Tomographic Angiography, Rest-Stress Millar Testing, Aortic vasorelaxation tests
Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 10, 2026, 2:29 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma

NCT02757326
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Opaganib
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 10, 2026, 2:29 PM EDT
Completed Not applicable Interventional

Targeted Hypothermia Versus Targeted Normothermia After Out-of-hospital Cardiac Arrest

NCT02908308
View directory record Official record
Conditions
Out-of-hospital Cardiac Arrest
Interventions
Targeted temperature management to 33°C, Standard care with early treatment of fever
Procedure
Lead sponsor
Helsingborgs Hospital
Other
Eligibility
18 Years and older
Enrollment
1,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Rochester, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 2, 2023 · Synced Sep 10, 2026, 2:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults

NCT07316608
View directory record Official record
Conditions
Healthy Participants
Interventions
Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 2, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 2, Laroprovstat Dose X STP, Rosuvastatin Dose 1 STP, Rosuvastatin Dose 2 STP
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 10, 2026, 2:29 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia

NCT02075463
View directory record Official record
Conditions
Anemia, Anaemia
Interventions
GSK1278863, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Azusa, California • Glendale, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 10, 2026, 2:29 PM EDT
Enrolling by invitation Phase 4 Interventional

Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan

NCT06034821
View directory record Official record
Conditions
Acute Suicidal Depression (ASD)
Interventions
Subanesthetic dose intravenous ketamine (KET), Electroconvulsive therapy (ECT)
Drug · Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
9
States / cities
San Francisco, California • Baltimore, Maryland • Belmont, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 10, 2026, 2:29 PM EDT